We are constantly developing our platform to create new functional possibilities and areas of service. We are continuously developing, broadening and refining the services we provide. Our aim is to continue being the most reliable and efficient provider of preclinical testing within immunology and immunotoxicity. We strive to develop even better solutions for evaluating investigational products with regard to their safety profile in human circulation. Development projects in pipeline:
B-cell malignancy model for safety and function
Testing a drug in patient-volunteers often results in “new knowledge”. We are looking into the benefits and the clinical relevance of testing drug-blood interactions in the target patient group already in the preclinical phase.
What parameters guide the selection of a safe starting dose? We are determining receptor occupancy and using it as one parameter to define the minimal anticipated biological effect level (MABEL) as the basis for calculating safer starting doses for first-in-man trials.
Autoimmune responses: multiple sclerosis, a model for safety and function
We are developing a disease-specific model for testing drug-blood interactions in fresh, circulating blood from patients with multiple sclerosis.